For millions of Americans managing chronic pain, the choice has long felt impossible: live with debilitating pain or risk opioid addiction. A new compound identified by researchers offers a potential third option: DFNZ. But the road from the lab to the medicine cabinet is long, and people are suffering now.

The Impossible Choice for Chronic Pain Patients

The opioid crisis didn’t start in darkened back alleys. It began in doctor’s offices, where patients with legitimate, life-altering pain were prescribed medications that worked, so much so that they didn’t let go.

Let’s be clear. Most people don’t start out wanting to get addicted. Rather, those with chronic pain often can’t get out of bed, go to work, or parent their children. Doctors handed them prescriptions that offered relief and dependence in the same bottle.

Up to 12% of patients who’ve used opioids for chronic pain develop addictions. This statistic sounds manageable until you apply it to tens of millions of prescriptions. A large fraction of patients currently suffering from opioid use disorder and dying from opioid overdoses had their first exposure as pain patients.

This tragedy lies at the center of the opioid epidemic that DFNZ researchers are trying to solve.

About DFNZ and Opioid Addiction

Researchers at the National Institute on Drug Abuse (NIDA), led by Dr. Michael Michaelides, have identified a novel synthetic compound called N-desethyl-fluornitrazene—DFNZ for short—that relieved pain in rodents without causing tolerance or other indicators of potential addiction.

In animal studies, DFNZ produced robust relief for acute and inflammatory pain. The novel drug didn’t cause significant respiratory depression or meaningful withdrawal effects with repeated dosing. 

NIDA Director Dr. Nora D. Volkow reported that “developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”

For chronic pain patients who have watched their prescription opioid dose climb over time, with tolerance building and withdrawal lurking, that statement carries enormous weight.

Chronic Pain Becomes Opioid Addiction

Chronic pain patients become so vulnerable to narcotic addiction because opioids interact with the brain over time. Research shows that opioid addiction primarily results from damage to the amygdala, leading to irregular reward-stress functions and heightened negative emotions during withdrawal that perpetuates the addiction cycle.

The cycle is cruel. Pain demands relief, opioids provide it, tolerance develops, higher doses are needed, and withdrawal becomes added suffering layered on top of the original pain. Many chronic pain patients describe not knowing where their pain ends and their opioid dependence begins.

Although alternatives to opioids exist to manage chronic pain, many people still fall back on prescriptions. Here’s where DFNZ, if it delivers on its early promise, can break this cycle at the molecular level.

DFNZ Differs From Fentanyl and Other Opioids

DFNZ activates the μ-opioid receptor, which is the same one targeted by morphine and fentanyl. The difference is that DFNZ doesn’t trigger the dopamine-driven reinforcement that leads to opioid addiction. This challenges the long-held assumption that strong μ-opioid activation inevitably causes dependence.

DFNZ belongs to a class of compounds roughly 1,000 times more potent than morphine, yet showing remarkably few adverse effects in preclinical models. For chronic pain sufferers who’ve built tolerance to regular opioids and require stronger doses for the same relief, the implications are significant.

Experts Urge Caution

History demands measured optimism. Oxycodone was once hailed as a safer, less addictive opioid. That promise contributed to the worst drug epidemic in American history.

Neuroscientists acknowledged DFNZ as a “promising approach,” but noted important limitations to address to avoid repeating the mistakes that led to the opioid crisis.

Significant additional research and regulatory scrutiny are required before any compound like DFNZ could reach the market. Human trials, FDA review, and years of post-market surveillance lie between today’s rodent data and a prescription pad. 

But for chronic pain patients with opioid addiction today, that timeline means more time  managing the pain and the drugs that have impacted their lives and those of loved ones.

Finding Help for Opioid Addiction While Managing Chronic Pain

Here’s where you can take steps today, rather than wait. If you’re living with chronic pain and opioid addiction, you’re not alone and you’re not to blame.

The first step often includes reaching out to your community for help and guidance. Going to grassroots, local groups for peer support works. Narcotics Anonymous offers anonymous, no-cost resources, sympathetic ears and shoulders, and assurance that you have help every step of the way. 

Getting started now is easier than it might seem. Call 800-934-1582(Sponsored) or browse our directory for comprehensive listings for group listings across the country.

For the first time in nearly a decade, opioid deaths are falling in Travis County, and public health officials say expanded access to naloxone (Narcan) is the primary reason. Drug-related deaths in the county dropped 22% from 2023 to 2024, and fatalities involving fentanyl fell by 36%. 

Travis County is home to a wide range of rehab services for drug addictions, from Narcotics Anonymous community meetings to modern inpatient hospitals. As with many counties in Texas, local and state officials have collaborated tirelessly to drive the death rate down, and these numbers show it. 

But advocates warn the progress is fragile, with federal funding cuts threatening to undo what took years to build.

The Opioid Crisis Hits Travis County

Travis County’s opioid crisis has been among the worst in the Lone Star State for years. The county’s seat and state capital, Austin, saw its peak of overdoses in mid-2023. And make no mistake, overdose deaths have remained the leading cause of accidental death in Travis County, ahead of both falls and motor vehicle accidents.

In January 2024, Austin-Travis County EMS averaged just over 100 opioid calls per month. By the next year, that number had dropped to about 50. A 50% drop occurred inside a single year.

Since 2022, Travis County has spent nearly $5 million on tackling the opioid overdose crisis and distributed more than 36,000 doses of Narcan to the community.

Driving the Decline in Opioid Deaths

Officials state clearly that opioid abuse hasn’t disappeared, but more people survive overdoses because the tools to reverse them are now within reach.

Officials noted this doesn’t necessarily mean fewer drugs are on the streets or that drug use itself is declining. Rather, mitigation methods reach more people.

EMS Division Chief Angela Carr said the availability of naloxone has been crucial, noting an increase of people administering Narcan prior to EMS arrival, which she called “instrumental” in affecting the death rate. 

Central Health, a nonprofit working with Travis County, is now expanding its fleet of naloxone distribution units, including to college campuses. The organization announced it will add 13 more Narcan distribution units to its existing 32, with all new sites ready by September. Officials plan to place four new units inside the Travis County Jail.

Fentanyl’s Role in the Austin Opioid Epidemic

Fentanyl has been the dominant driver of opioid deaths in Travis County throughout the crisis. The 2024 medical examiner’s report was a stark contrast to the prior year’s findings, which revealed the highest rate of accidental overdoses ever recorded in Travis County.

Fentanyl is a synthetic opioid 50-100x more potent than morphine. It contaminates the illicit drug supply broadly, including pills, heroin, and even stimulants like cocaine. This means people with any substance use disorder face fentanyl exposure risk. Naloxone (Narcan) is a medication approved by the FDA that rapidly reverses opioid overdoses and is available without a prescription in most states, including Texas.

Experts recommend that everyone learn to recognize overdose signs, such as small pupils, decreased responsiveness, and slow or absent breathing. Anyone who finds someone showing those signs should use naloxone immediately and call 911, since fatal opioids typically last longer than a single dose of intranasal naloxone.

Opioid Settlement Funding & the Federal Threat

Much of the progress in Travis County is financed by legal settlements with opioid manufacturers. Settlements from lawsuits against pharmaceutical companies have brought hundreds of thousands of dollars each year to fund Narcan doses and install the distribution units.

But that funding stream faces serious risk. Many nonprofits rely on COVID-19 era federal grants that might disappear after the Trump administration announced plans to cut $11.4 billion in addiction and mental health services. Texas Harm Reduction Alliance Executive Director Maggie Luna warned that without sustained investment, the progress made in lowering fatal drug overdoses could be at risk. 

Treatment Options and NA Meetings in Austin

Recovery from opioid addiction requires more than surviving an overdose. Travis County has invested in a range of treatment pathways alongside its harm reduction work. The county has launched public education campaigns and trained 1,000+ community members to recognize and respond to overdoses.

Austin-Travis County EMS has also emphasized a buprenorphine bridge program as a way of helping people by connecting those who survive an overdose with medication-assisted treatment before they leave EMS care.

For those seeking peer support, Narcotics Anonymous (NA) meetings remain a cornerstone of long-term recovery from opioid and narcotic addiction. NA meetings in the Austin and Travis County area are available daily, in-person and online, for anyone ready to take the next step.

Perhaps best of all, NA meetings are peer-led. You meet with others in your community who have the same experiences and backgrounds, and camaraderie forms for life-long support and fellowship. Our directory has a comprehensive list of NA meetings across the county, or feel free to call 800-934-1582(Sponsored) to speak to an expert.

The University of Idaho is working to close a critical gap in opioid addiction care that has already cost hundreds of lives in the state. A program is training Idaho clinicians on treating opioid use disorder. The goal is to equip frontline providers with the updated knowledge as fentanyl, xylazine, and other substances continue to reshape the opioid crisis across the state.

Idaho already has an impressive range of programs available to combat substance misuse. In the Gem State, local communities have banded together to start grassroots chapters of Narcotics Anonymous to offer peer support for those impacted by drug use.

Yet a significant share of people never receive proven treatment and a lack of trained providers is a major reason why. The need persists, with 264 Idahoans dying from opioid-related drug overdoses in 2023. 

The Opioid Crisis

The treatment gap is especially pronounced in rural states like Idaho, where access to opioid treatment programs (OTP) is limited by geography. While 20% with opioid use disorder achieve two years of abstinence without meds, those who relapse face a high risk of death. This makes medication-assisted treatment (MAT) a life-or-death issue for thousands of patients.

After someone has overdosed once, the chance of dying within the next year is one in ten.

The Opioid Care Gap in Idaho

According to Dr. Jacob Harris, an addiction medicine specialist at the VA Medical Center in Boise, one reason so few people receive medication is that Idaho’s health care community isn’t sufficiently trained to confidently treat the condition. Reticence is driven by lack of training, not knowing where to start and fear of doing it incorrectly. 

Under the University of Idaho’s School of Health and Medical Professions, Project ECHO Idaho operates the Opioids, Pain and Substance Use Disorders (OPSUD) series. Physicians, nurse practitioners and other primary care clinicians learn about the latest theories and practices for treating substance use disorders and pain.

The online series equips Idaho health care workers to prescribe meds and treat patients as laws, addiction trends and treatment recommendations change.

Fentanyl’s Role & the Shifting Drug Landscape

The opioid crisis hasn’t stood still. The opioid landscape has evolved over the past several years as people move from prescription opioids to street oxycodone, then heroin and now fentanyl. Illegal dealers often lace these opioids with other substances to intensify their effects.

Today, new drugs have emerged. Xylazine is a non-opioid veterinary tranquilizer that slows the heart rate and produces long-lasting euphoria and emerged in U.S. drug supplies in the early 2000s. Kratom is a non-federally regulated drug that mimics opioid-like sedative and euphoric effects and has impacted Idaho for more than a decade.

The 2025 OPSUD series consisted of learning how to ID, test and treat addiction or overdoses involving these substances.

One session highlighted a lesser-known fentanyl overdose symptom called “wooden chest syndrome,” in which rigid chest muscles make breathing extremely difficult. It’s a sobering reminder that even experienced clinicians have more to learn.

Medications and Expanding Access

The two primary medications for opioid use disorder are methadone, usually dispensed through opioid treatment programs, and buprenorphine, which patients can take at home. Since methadone is only available through OTP facilities typically located in larger cities, buprenorphine has expanded access to life-saving treatment in rural areas.

In addition, naloxone (brand name Narcan) is an emergency medication that can reverse an opioid overdose within minutes.

Prior to 2023, prescribers had to complete special DEA X-waiver training to prescribe medications for opioid use disorder. That requirement was removed. Now, with eight hours of continuing education per year, prescribers are licensed to provide controlled medications. The OPSUD series meets these requirements.

Harm Reduction & NA

Medication and clinical care comprise only part of the solution. Peer support and community-based recovery play a vital role in long-term opioid addiction recovery.

For many Idahoans, Narcotics Anonymous (NA) meetings provide free, peer-led support for people struggling with narcotic addiction at every stage of recovery. NA meetings are available in communities across Idaho in-person and online.

A landmark loan repayment initiative in Michigan is putting real money behind the push to close a devastating gap in opioid addiction treatment, and it could mean more help is finally coming to communities hardest hit by the opioid crisis.

Michigan’s Department of Health and Human Services (MDHHS) is offering student loan repayment to providers who begin or expand opioid addiction treatment programs, with awards ranging from $15,000 to $30,000.

The Opioid Crisis by the Numbers

The need driving this program is staggering. An estimated 1.3 million Michigan residents need treatment for substance use disorder but are not currently receiving it, according to the National Survey on Drug Use and Health. Workforce shortages are a central reason why.

Michigan currently ranks 40th in the nation in the number of substance use disorder counselors per adult with a disorder, a gap that leaves people with opioid addiction waiting for care that often never arrives. For many, that wait ends in overdose.

What Is Driving the Treatment Gap

The barriers keeping providers out of this field are well documented. High educational debt and the cost of addiction medicine certification deter many qualified clinicians from entering opioid treatment, particularly in rural and underserved areas.

Michigan’s loan repayment initiative is supported by the Michigan Opioid Healing and Recovery Fund, created using settlement funds from the nation’s three largest pharmaceutical distributors and opioid manufacturer Johnson and Johnson.

To date, the program has provided $3.7 million in loan repayment assistance to 202 providers and helped treat an additional 8,000 opioid use disorder clients.

Those are 8,000 people who got access to opioid addiction treatment they might not otherwise have received.

Who Is Eligible and How to Apply

Medical and osteopathic doctors, psychiatrists, nurse practitioners, physician assistants, case managers and substance use disorder counselors are eligible to apply if they are offering or expanding opioid treatment services.

Providers must serve at least two to three years at an approved substance use disorder treatment facility. For the current cycle, applications are being accepted through the MIOTA program portal at Michigan.gov/miota.

Fentanyl and the Ongoing Overdose Emergency

Programs like this exist because the opioid epidemic has not slowed. Fentanyl, a synthetic opioid up to 100 times more potent than morphine, now drives the overwhelming majority of overdose deaths in the United States.

It has infiltrated the street supply of heroin and counterfeit pills, making every use potentially fatal.

Expanding access to opioid addiction treatment, including medication-assisted treatment (MAT) with buprenorphine or methadone, is one of the most effective tools public health officials have to reduce overdose deaths.

Understanding Opioid Addiction and Treatment Options

Opioid addiction, also called opioid use disorder (OUD), is a chronic medical condition driven by changes in brain chemistry caused by repeated opioid exposure, whether from prescription painkillers, heroin or illicit fentanyl.

Effective opioid addiction treatment typically combines FDA-approved medications with behavioral health counseling.

Naloxone (Narcan) remains a critical life-saving intervention that can reverse an opioid overdose in minutes and is available without a prescription in most states.

Harm Reduction and Peer Recovery Through Narcotics Anonymous

Expanding the provider workforce addresses one side of the treatment gap. Peer recovery is the other. Narcotics Anonymous (NA) meetings offer free, community-based support for anyone struggling with narcotic addiction or opioid abuse, no referral or insurance required.

NA meetings operate on lived experience: people who have been through opioid addiction supporting others who are still fighting it.

For people not yet ready for formal treatment, or as a complement to medication-assisted therapy, NA meetings are a critical first step toward recovery.

Finding Help for Opioid Addiction

You can find Narcotics Anonymous meetings nationwide by searching Narcotics.com’s directory of NA meetings. Meetings are available in person and online, seven days a week. Call 800-934-1582(Sponsored) to speak with a treatment advisor today.

A Chattanooga nonprofit is placing a free naloxone dispenser in Miller Park, one of the city’s most-visited public spaces. It’s a direct effort to put life-saving opioid overdose reversal medication in the hands of people who need it most. 

North Carolina boasts plenty of programs to battle opioid addiction no matter where you’re located in the Tar Heel State. But for family members who fear getting that call, a naloxone dispenser can mean the difference between life and death.

The Opioid Crisis in Chattanooga by the Numbers

The numbers behind this initiative are impossible to ignore. One recent study found that naloxone prevented at least 2,400 overdoses around Chattanooga in 2023 alone. That figure reflects both the depth of opioid addiction afflicting Tennesseans and the proven power of naloxone as a frontline intervention. The surrounding region around Hamilton County and the greater Chattanooga area have consistently ranked among the state’s harder-hit regions for opioid-related harm.

What Launch Pad Does and Why It Matters

Launch Pad is a sober living program nonprofit that received a county grant to fund a newspaper-style dispenser box stocked with free naloxone for those who can’t afford Narcan. The box will hold at least 10 packages at all times and sit in a shaded corner of Miller Plaza. The Chattanooga City Council unanimously approved the proposal. 

Launch Pad’s clinical director, Kelli Cruse, acknowledged that supplies will likely go fast at first, but that’s exactly the point. “We want this medication out to the people who are going to use it,” Cruse noted, adding that once people realize that it will be a permanent fixture, they’ll only take what they need.

As for concerns about potential misuse and side effects, Launch Pad leadership noted that the pros of saving lives outweigh any cons. “The risk of not having it is greater than the risk of having it and it being in the wrong hands,” Cruse pointed out. 

Fentanyl’s Role in the Overdose Emergency

The need for naloxone is great. Fentanyl is now the primary driver of opioid overdose deaths in all age groups, and naloxone has proven effective in countering overdoses. According to the CDC, nasal spray or injectable naloxone blocks the effects of opioids and restarts normal breathing in unresponsive overdose victims.

Furthermore, the medication has no effect on a person who does not have opioids in their system. Naloxone’s nontoxicity makes it safe for bystanders, family members, and first responders to carry and use without fear of causing harm.

A Growing Trend Across Tennessee and the U.S.

Chattanooga isn’t alone in this approach. Naloxone dispensers and kiosks have become popular devices in Nashville, Knoxville and other cities for their practicality, including in music venues and bars as part of first aid response.

Public health agencies and nonprofit partners across the country are deploying dispensers. Cities in California, Kentucky, and Iowa have made naloxone available in public spaces such as train stations and college campuses. The number has exploded from an estimated 80 nationwide in 2022 to hundreds today.

Harm Reduction and Opioid Treatment Options in Chattanooga

Remember that naloxone is a bridge, not a treatment for opioid addiction itself. For those struggling with opioid addiction in the Chattanooga area, several pathways to recovery exist alongside harm reduction tools like this dispenser. Even something as basic as attending a Narcotics Anonymous class can connect you with peers who understand your condition.
If you or someone you love is at risk of opioid addiction or an overdose, browse our directory for a nearby support group that fits your needs or call 800-934-1582(Sponsored) to start the battle against narcotics in your life.

Washington state’s Native communities are confronting a fentanyl and opioid addiction crisis with one of the most reliable life-saving tools available, naloxone.

Overdose death rates among American Indian and Alaska Native populations continue to outpace every other demographic in the United States.

Expanded access to the overdose-reversing medication is offering a critical line of defense while tribal leaders push for deeper, culturally grounded treatment solutions.

The Opioid Crisis by the Numbers

The scope of opioid addiction among Native populations is staggering. The American Indian and Alaska Native population has the highest drug overdose death rates in the country.

Statistics show a 33% increase in drug overdose deaths recorded between 2020 and 2021, according to the Centers for Disease Control and Prevention.

Washington state reflects these national trends with alarming clarity. Roughly 65% of all drug deaths in Washington involved synthetic opioids, primarily fentanyl, totaling more than 1,700 deaths in a single year, according to the University of Washington’s Addictions, Drug and Alcohol Institute.

Last year also marked King County’s deadliest year ever for fatal overdoses, with more than 700 involving fentanyl. The human cost inside tribal communities has been devastating.

Lummi Nation Chair Tony Hillaire spoke at the Washington State Tribal Opioid/Fentanyl Summit about the losses his community has endured.

He noting that five members died of fentanyl overdoses in just one week, a crisis severe enough that Lummi leaders declared a state of emergency. “We don’t want to normalize the burying of our children,” Hillaire said.

Fentanyl’s Role in the Native Community Crisis

Fentanyl, a synthetic opioid roughly 50 times more potent than heroin, has proven a particularly difficult threat for tribal communities to address, straining existing clinics and treatment options across Washington and in some cases creating long waitlists for care.

The roots of opioid addiction in Native communities run deep. Indigenous families have confronted substance use disorders for decades as a downstream consequence of centuries of violence, forced family separation, boarding school trauma and the deliberate destruction of tribal economies.

All factors that increase vulnerability to addiction. Poverty, housing insecurity and chronic underinvestment in tribal health infrastructure have compounded that vulnerability as fentanyl moved in. If you or loved one need support with narcotics addiction recovery, you can explore numerous NA meetings in Washington.

Naloxone Distribution Reaches Native Communities

Washington’s state health agencies have moved aggressively to get naloxone, the medication that reverses opioid overdoses, into the hands of people most at risk.

In fiscal year 2025 alone, Washington’s Overdose Education and Naloxone Distribution (OEND) program and its partners distributed approximately 365,306 naloxone kits and held 76 training events reaching more than 1,500 individuals.

Critically, the state’s mail-order naloxone program has proven especially effective at reaching Native populations.

American Indian and Alaska Native community members are more likely to receive naloxone through the mail-order program than through other distribution channels.

Tribes, tribal organizations and Urban Indian Organizations can also request naloxone directly through a dedicated Tribal Naloxone Request Form administered by the Washington State Department of Health.

Still, advocates are clear that naloxone alone cannot solve the opioid addiction crisis. As one addiction specialist at UW Medicine put it, naloxone reverses an overdose for only 30 to 90 minutes, it is a critical intervention, but treatment, support and destigmatization must follow.

What’s Driving the Push for Culturally Grounded Treatment

Tribal health providers in Washington have long argued that opioid addiction treatment works best when it integrates Indigenous cultural traditions alongside Western medicine.

Organizations like the Seattle Indian Health Board use a model called Indigenous Knowledge Informed Systems of Care, blending modern treatment protocols with traditional practices and culturally attuned care, an approach that has produced meaningful results even in the fentanyl era.

Tribal leaders, health providers and state officials broadly agree that more funding is needed, particularly in Native communities, to staff health care centers, open more inpatient beds, expand medication-assisted treatment centers and ensure wider access to naloxone.

At the federal level, the National Institutes of Health has taken notice. NIH launched a dedicated program to advance substance use research led by Native American communities, with a second phase of expanded capacity-building research anticipated to begin in fall 2026.

Understanding Opioid Addiction and Naloxone

Opioid addiction is a chronic, relapsing medical condition driven by dependence on substances such as heroin, fentanyl, prescription painkillers like oxycodone and methadone.

Fentanyl, now the dominant driver of overdose deaths nationally, is particularly dangerous because it is often mixed into counterfeit pills and other substances without the user’s knowledge, making every use a potential overdose risk.

Naloxone (brand name Narcan) is an FDA-approved medication that rapidly reverses opioid overdose when administered as a nasal spray or injection, and is available without a prescription in Washington state.

Opioid Addiction Treatment Options

For anyone struggling with opioid addiction, multiple treatment options exist. Narcotics.com provides a directory of NA meetings, including in and near tribal communities. You can also call 800-934-1582(Sponsored) to receive additional support today.

For anyone touched by opioid addiction, whether personally or through someone they love, the statistics are both heartbreaking and familiar.

Too many pain journeys end not in recovery, but in dependence, overdose or death. Now, a wave of new treatments and federal policy shifts are aiming to break that cycle before it begins.

The Opioid Crisis by the Numbers

Overdose deaths remain staggering. According to the CDC, roughly 79,384 people died from drug overdoses in 2024, a 26.2% drop from the more than 110,000 deaths recorded in 2023.

Progress, yes, but not nearly enough. In the 12-month period ending August 2025, approximately 73,000 people still died from overdoses.

Beyond fatalities, more than 40 million Americans reported struggling with a substance use disorder in 2024.

For families searching for help, those numbers represent real people, parents, siblings, children, many of whom first encountered opioids through a legitimate prescription for pain.

How Opioid Abuse Begins with Pain Treatment

The opioid epidemic didn’t emerge from a vacuum. It grew, in large part, from a healthcare system that defaulted to opioid prescriptions as the primary answer to pain.

For decades, the American approach to pain management has been caught in a dangerous paradox. Prescribing addictive opioids to treat injury, only to create a secondary crisis of addiction.

This is particularly acute after procedures like spine surgery, where many addictions arise from high opioid use in the first days of recovery, a window when patients are vulnerable and alternatives have historically been limited or not covered by insurance.

Fentanyl’s Role in Driving Overdose Deaths

The ongoing death toll is largely driven by synthetic opioids like fentanyl. Fentanyl is estimated to be 50 to 100 times more potent than morphine, and it now contaminates the broader illicit drug supply.

This means people struggling with heroin addiction or other narcotic addiction are frequently exposed to it unknowingly.

Naloxone (brand name Narcan) remains the frontline life-saving response to opioid overdose.

It is available without a prescription at most pharmacies and through harm reduction programs.

If someone in your life is using opioids, prescribed or otherwise, having naloxone on hand can mean the difference between life and death.

What’s Driving the Change in Pain Management

President Trump’s January 2025 executive order establishing the “Great American Recovery Initiative” builds on two key federal actions, the HHS Pain Management Best Practices Inter-Agency Task Force and the bipartisan No PAIN Act.

The No PAIN Act expands and incentivizes Medicare coverage for non-opioid pain treatments in surgical settings, directly addressing the financial barrier that has historically made opioids the default, cheaper choice.

The goal, advocates say, is to prevent opioid addiction from starting in the first place, treating pain without creating the conditions for dependence.

New Non-Opioid Treatments Showing Promise

Several promising alternatives are now moving from research into real-world use. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid oral medication that targets pain-signaling sodium channels in the peripheral nervous system rather than the brain.

It’s an approach that offers acute pain relief without the addiction risk associated with opioids.

Electrical therapies are also advancing, including closed-loop spinal cord stimulation, peripheral nerve stimulation and Basivertebral Nerve Ablation.

These systems use low-voltage electrical currents to interrupt pain signals, improving function and quality of life while reducing opioid exposure and healthcare utilization.

These technologies won’t undo existing opioid addiction, but they represent a real chance to reduce the pipeline of new cases.

Finding Help for Opioid Addiction

If you or someone you love is already struggling with opioid or narcotic addiction, treatment works, and peer support through Narcotics Anonymous is one of the most accessible entry points to recovery.

Search Narcotics.com’s directory of NA meetings to find an option near you. You can also call 800-934-1582(Sponsored) to speak with a treatment advisor today.

The Bay Area Rapid Transit system, the largest public transportation network in the region, has emerged as one of the most visible arenas of California’s opioid epidemic. As opioid overdoses mounted onboard BART, the agency began equipping officers and staff with naloxone kits.

It’s a harm reduction measure that has since become central to how the system responds to the crisis. For thousands of daily riders, encountering opioid use and its consequences has nonetheless become a routine part of the commute, and for many, a reason to stop riding altogether.

The Opioid Crisis by the Numbers

More than 19 overdoses occurred on BART property in 2023 alone, according to reporting by The San Francisco Standard. It’s a figure already on pace to surpass the overdose death count from 2022.

The crisis continued into late 2025, when two passengers suffered narcotics overdoses on separate BART trains in the East Bay within a 48-hour window. Ridership has suffered alongside public health, with CBS News reporting a measurable decline in BART passengers in 2023 driven by commuter concerns over safety and the growing frequency of opioid-related medical emergencies.

How BART Naloxone Kits Are Saving Lives

BART first introduced naloxone nasal spray, commonly known by the brand name Narcan, in May 2019. Since then, the agency has significantly expanded the program, equipping officers and frontline staff with BART naloxone kits as standard gear.

According to ABC 7 News, deployments have grown more than sixfold over three years, rising from 29 in the first year to 188 annually. By March 2024, those interventions had successfully reversed more than 400 overdoses on BART premises.

To sustain that response capacity, BART reports that all police officers now receive formal training in naloxone administration. The kits are kept in officer toolkits at all times, ensuring a reversal agent is available anywhere on the system when an overdose occurs.

The agency has also expanded its corps of Crisis Intervention Specialists, which are trained staff focused on connecting people experiencing opioid use disorder with treatment resources rather than defaulting to arrest.

Fentanyl’s Role in the Transit Crisis

Fentanyl, a synthetic opioid estimated to be roughly 50 times more potent than the effects of heroin, is the primary driver of overdose deaths across the United States and a dominant presence in the Bay Area’s drug supply. Its extreme potency means that small variations in dose can be lethal, and illicitly manufactured fentanyl is now found in a wide range of street drugs, often without the user’s knowledge.

This is precisely why rapid access to BART naloxone kits is so consequential. In a fentanyl overdose, minutes determine survival.

Youth and Families Bear a Hidden Cost

Students and young commuters who depend on BART to reach school face a particular burden. Research published in Clinical Therapeutics found that exposure to adult substance use increases the likelihood that young people will develop substance use problems and mental health conditions of their own.

These encounters can also contribute to adverse childhood experiences (ACEs), a recognized framework linking early trauma to prolonged stress and long-term psychological harm. It illustrates the lasting impact of parental opioid abuse.

Understanding Opioid Addiction and Overdose Risk

Opioids are a class of drugs that include fentanyl, heroin, oxycodone, and other prescription painkillers. They act on receptors in the brain to reduce pain but also suppress breathing, which is what makes an overdose fatal. Narcotic addiction is a chronic medical condition, not a moral failure, and it responds to evidence-based treatment including medication-assisted therapy and peer recovery programs like Narcotics Anonymous.

Naloxone is available without a prescription at most pharmacies in California. If someone is unresponsive and opioid use is suspected, call 911 and administer naloxone immediately, fentanyl overdoses may require more than one dose. Free naloxone and fentanyl test strips are available through harm reduction organizations across the Bay Area.

Find Local NA Meetings

An important part of a successful recovery is having the support of peers who understand what you’re going through. Search Narcotics.com’s directory to find local NA meetings to start receiving support today. You can also call 800-934-1582(Sponsored) for additional assistance.

For people in Virginia’s Roanoke Valley, harm reduction backpacks are helping prevent opioid overdoses.

These backpacks are designed to help individuals at risk for opioid overdose and contain naloxone, a medication that can quickly reverse an overdose in an opioid overdose emergency. 

A community-based effort, Connection to Care (C2C) is at the heart of this opioid addiction outreach work, supported early on by a 2018 seed grant from the Vibrant Virginia initiative.

The effort connects universities and communities to work together on building practical solutions for local social challenges. 

While Roanoke offers several approaches to addressing opioid addiction and substance use disorders, the Connection to Care backpacks have already impacted thousands of lives and for the better.

Discover NA Meetings in Roanoke to receive peer support to help with your recovery.

Harm Reduction Backpacks Help Prevent Opioid Overdose

So far, C2C has provided backpacks for residents who might lack access to critical resources. The backpacks include essential supplies and connect recipients to addiction recovery services. Students and local volunteers play key roles in delivering the packs to those who need them most. 

What the small seed grant from Vibrant Virginia has accomplished is a far reaching response to the opioid crisis in Virginia.

Initial efforts focused on understanding substance use disorders in the Roanoke Valley and Pulaski County and emphasized first identifying local needs and building trust with community partners. 

Vibrant Virginia first partnered with the Virginia Harm Reduction Coalition and the Bradley Free Clinic. Collaboration with both organizations helped shape the program’s approach.

Together, they developed a model centered on direct outreach in the community, which made it easier to offer practical support to individuals facing opioid addiction. 

The C2C program and its outreach has resulted in over 8,000 contacts with at-risk individuals and harm reduction services or treatment support provided to more than 4,000 folks.

The program’s focus is on offering immediate help, but there’s also emphasis on creating pathways to long term recovery.

Opioid Addiction Response Expands Across Virginia

The success of C2C’s efforts in the community led to nearly $1 million in federal funding. Those dollars allowed for expansion of services and the introduction of new initiatives.

One example is Responders for Recovery, which pairs peer recovery specialists to support individuals after opioid overdoses.

The federal funding not only allows the program to offer more services, funds also help health providers, law enforcement and community organizations coordinate together.

That means more people can get help when they need it without having to wait for resources to become available.

The Vibrant Virginia backpacks illustrate how targeted funding and team effort can produce sustainable solutions to complex public health challenges. 

Find NA Meetings and Opioid Addiction Support

Don’t let a lack of resources or tight finances prevent you from starting recovery. There are many addiction treatment services in Virginia that can assist you.

Search Narcotics.com’s directory to find local Narcotics Anonymous meetings right in your community. Call today at 800-934-1582(Sponsored) for immediate assistance.

For anyone struggling with opioid addiction today, the path to recovery just got more complicated. A major new national study confirms what many addiction medicine doctors have been seeing on the front lines for years.

Fentanyl, the synthetic opioid that now dominates the illicit drug supply, is making it significantly harder to start patients on buprenorphine, one of the most effective and accessible medications for opioid use disorder.

The findings, published in JAMA Network Open and led by researchers at Penn State College of Medicine and the University of Pittsburgh, are a wake-up call for anyone affected by the opioid epidemic.

This includes patients, families and the healthcare providers trying to help them.

The Opioid Crisis by the Numbers

The survey of 396 clinicians across the United States paints a sobering picture of where opioid addiction treatment stands right now:

Nearly 72% of clinicians reported significant challenges starting patients on buprenorphine when fentanyl was involved. Close to 62% encountered at least one case of sudden, severe withdrawal, sometimes called precipitated withdrawal, when initiating treatment.

More than half, 52.8%, reported cases where withdrawal symptoms dragged on for days rather than the expected hours. And approximately 67% said they’ve had to change their standard treatment protocols to adapt.

These aren’t just statistics. Each one represents a real person trying to get clean who hit a wall.

What’s Driving the Change

Treating opioid addiction used to follow a relatively predictable script. When heroin was the dominant drug, clinicians could confirm use through drug screening and start patients on buprenorphine at established doses and intervals with reliable results. That consistency saved lives.

Fentanyl changed the equation starting around 2017, when it began flooding the illicit opioid supply. The problem isn’t just that fentanyl is more potent — it’s how the drug behaves in the body. Fentanyl can accumulate in fat tissue, where it lingers long after a person’s last use.

When buprenorphine is introduced, it can displace fentanyl from opioid receptors and trigger intense withdrawal far more severe and prolonged than what patients experienced during the heroin era.

“Someone can get really sick or get tired of the whole process that they stop treatment,” said lead author Dr. Sarah Kawasaki of Penn State College of Medicine. “They might start using again and might overdose or die.”

That cycle of withdrawal, dropout, relapse and overdose is one of the most devastating patterns in the current opioid epidemic.

Fentanyl’s Role in the Treatment Gap

Fentanyl is now present in the vast majority of illicit opioid supply in the United States. It has also been found in counterfeit pills and other street drugs, meaning people with opioid addiction are often exposed to it even when they don’t intend to be.

Its unique pharmacology, high potency, rapid onset, and fat-soluble accumulation, means the clinical playbook written for heroin simply doesn’t apply. Clinicians surveyed in the study responded in a variety of ways.

Some dramatically lowered initial buprenorphine doses, others went higher, some added medications to manage withdrawal symptoms and others redirected patients entirely to inpatient treatment or methadone programs.

The patchwork of adaptations reflects a field working without updated, evidence-based guidelines and patients paying the price for that gap.

Understanding Opioids and Overdose Risk

Opioids are a class of drugs, both prescription medications and illicit substances like heroin and fentanyl, that bind to receptors in the brain and body to reduce pain and produce euphoria.

Fentanyl is a synthetic opioid estimated to be 50 to 100 times more potent than morphine, making even a tiny amount potentially lethal. Opioid overdose occurs when the drug suppresses breathing to the point of oxygen deprivation; naloxone (Narcan) can reverse an overdose if administered quickly enough.

Harm Reduction and Treatment Options

Despite the challenges, researchers are emphatic that buprenorphine still works, and it remains one of the most accessible opioid addiction treatments available.

Unlike methadone, which can only be dispensed through approximately 2,000 licensed clinics nationwide, buprenorphine can be prescribed by qualified providers and filled at more than 70,000 pharmacies across the country.

If you or someone you love is struggling with opioid addiction, harm reduction steps include:

1. Carry naloxone (Narcan): Available without a prescription at many pharmacies and through community harm reduction programs. It can reverse an opioid overdose and save a life.
2. Use fentanyl test strips: These low-cost tools can detect fentanyl in a drug supply before use.
3. Talk to a doctor about medication-assisted treatment: Buprenorphine and methadone are both evidence-based options for opioid use disorder.
4. Connect with peer support: Narcotics Anonymous (NA) meetings provide community, accountability, and lived experience that clinical treatment alone can’t offer.

Finding Help for Opioid Addiction

NA Meetings Near You Narcotics Anonymous offers free peer support meetings in thousands of locations. Search for NA meetings in your city or state to find in-person and virtual options near you.

Opioid Treatment Programs Ask your primary care provider about buprenorphine, or search SAMHSA’s treatment locator at findtreatment.gov for opioid treatment programs near you.

Call for Help: SAMHSA’s National Helpline (1-800-662-4357) is free, confidential and available 24/7 for opioid addiction treatment referrals.

Harm Reduction Callout: Naloxone saves lives. If someone in your life uses opioids, or if you do, having naloxone on hand is one of the most important steps you can take. Many local health departments and harm reduction organizations distribute it for free.